Mighty Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 39 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.32 Cr
- Revenue Growth 28.44%
- Profit Growth -4.32%
- Ebitda -44.28%
- Net Worth 22.67%
- Total Assets 32.07%
About Mighty Pharma
Mighty Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 April 1985 and has a history of 39 years and ten months. Its registered office is in Vasai, Maharashtra.
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹5.32 Cr.
Dhaval Talati, Mukti Jain, and Siddhi Gandhi serve as directors at the Company.
Company Details
- Location Vasai, Maharashtra
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230MH1985PTC035874
-
Company No.
035874
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Apr 1985
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Mighty Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhaval Talati
|
Director | 02-May-2009 | Current |
|
Mukti Jain
|
Director | 15-Apr-2004 | Current |
|
Siddhi Gandhi
|
Director | 15-Apr-2004 | Current |
Financial Performance of Mighty Pharma.
Mighty Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 28.44% increase. The company also saw a slight decrease in profitability, with a 4.32% decrease in profit. The company's net worth Soared by an impressive increase of 22.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mighty Pharma?
In 2021, Mighty Pharma had a promoter holding of 46.20% and a public holding of 53.80%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Nem Laboratories Pvt LtdDhaval Talati, Mukti Jain and 1 more are mutual person
-
Neelanjay Resources LlpDhaval Talati and Siddhi Gandhi are mutual person
Charges (Loans)
₹53.20 M
₹0
Charges Breakdown by Lending Institutions
- Others : 5.30 Cr
- Canara Bank : 0.02 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Sep 1994 | Others | ₹5.30 Cr | Open |
| 06 Dec 1991 | Canara Bank | ₹0.20 M | Open |
How Many Employees Work at Mighty Pharma?
Mighty Pharma has a workforce of 11 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mighty Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mighty Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
